416 related articles for article (PubMed ID: 30670769)
1. Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes.
Wang Z; Liu W; Chen C; Yang X; Luo Y; Zhang B
Sci Rep; 2019 Jan; 9(1):253. PubMed ID: 30670769
[TBL] [Abstract][Full Text] [Related]
2. Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer.
Takada K; Kashiwagi S; Asano Y; Goto W; Kouhashi R; Yabumoto A; Morisaki T; Shibutani M; Takashima T; Fujita H; Hirakawa K; Ohira M
BMC Cancer; 2020 Jun; 20(1):598. PubMed ID: 32590956
[TBL] [Abstract][Full Text] [Related]
3. Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours.
Chen B; Zhang G; Lai J; Xiao W; Li X; Li C; Mok H; Li K; Wang Y; Cao L; Jia M; Ren C; Wen L; Wei G; Lin J; Li Y; Zhang Y; Chen X; Wu X; Zhang H; Li M; Liu J; Balch CM; Liao N
EBioMedicine; 2021 Sep; 71():103542. PubMed ID: 34454403
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement.
Macchetti AH; Marana HR; Silva JS; de Andrade JM; Ribeiro-Silva A; Bighetti S
Clinics (Sao Paulo); 2006 Jun; 61(3):203-8. PubMed ID: 16832552
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer.
Solis-Castillo LA; Garcia-Romo GS; Diaz-Rodriguez A; Reyes-Hernandez D; Tellez-Rivera E; Rosales-Garcia VH; Mendez-Cruz AR; Jimenez-Flores JR; Villafana-Vazquez VH; Pedroza-Gonzalez A
Breast Cancer; 2020 Sep; 27(5):837-849. PubMed ID: 32180141
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
8. lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer.
Zhang Y; Li Z; Chen M; Chen H; Zhong Q; Liang L; Li B
Breast Cancer; 2020 Jul; 27(4):573-585. PubMed ID: 31960363
[TBL] [Abstract][Full Text] [Related]
9. Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors.
Glajcar A; Łazarczyk A; Tyrak KE; Hodorowicz-Zaniewska D; Streb J; Okoń K; Szpor J
Virchows Arch; 2021 Nov; 479(5):871-882. PubMed ID: 34117905
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40.
Ramstad T; Lawnicki L; Vetto J; Weinberg A
Am J Surg; 2000 May; 179(5):400-6. PubMed ID: 10930490
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
[TBL] [Abstract][Full Text] [Related]
12. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C; Chen J; Chen L
Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
[TBL] [Abstract][Full Text] [Related]
13. Possibility of avoiding axillary lymph node dissection by immune microenvironment monitoring in preoperative chemotherapy for breast cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
J Transl Med; 2018 Nov; 16(1):318. PubMed ID: 30454008
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
15. Memory CD4
Vahidi Y; Faghih Z; Talei AR; Doroudchi M; Ghaderi A
Cell Oncol (Dordr); 2018 Feb; 41(1):1-11. PubMed ID: 28994018
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.
Bai F; Jin Y; Zhang P; Chen H; Fu Y; Zhang M; Weng Z; Wu K
Aging (Albany NY); 2019 Nov; 11(21):9328-9347. PubMed ID: 31715586
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of lymph nodes metastasis associated genes in cervical cancer and its significance in treatment and prognosis.
Yang P; Ruan Y; Yan Z; Gao Y; Yang H; Wang S
BMC Cancer; 2021 Nov; 21(1):1230. PubMed ID: 34789197
[TBL] [Abstract][Full Text] [Related]
18. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
20. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
